USA Solid Tumor Therapeutics Market Outlook to 2028

Market Overview:

The USA Solid Tumor Therapeutics Market refers to the pharmaceutical & biotechnology sector focused on developing & marketing treatments for various types of solid tumors, which are cancerous growths that forms in the tissues such as the breast, lung, prostate, colon & more. The market consists of wide range of therapies, including chemotherapy, targeted therapies, immunotherapies & emerging approaches like gene & cell therapies. United States holds a significant share in the solid tumor therapeutics market.

Solid tumors are a significant healthcare concern in the United States, contributing to a significant portion of cancer cases & mortality. The prevalence of various types of tumors, such as breasts, lungs & colorectal cancers, has driven the demand for therapeutic options. Advancements in our understanding about cancer biology, genomics, & molecular pathways have led to development of targeted therapies that can specifically target the underlying genetic mutations driving tumor growth. These targeted therapies often have fewer side effects. The concept of personalized medicine has gained traction, allowing for tailored treatment approaches based on an individual's genetic makeup. Some leading players within the market include AstraZeneca, Novartis, Pfizer etc. They're known for providing certain therapies for different types of solid tumor.

USA Solid Tumor Therapeutics Market is a mix of consolidated & fragmented players. It is dominated by several large pharmaceutical players like AstraZeneca, Ipsen, Pfizer etc. which sell a wide range of products targeting various types of products targeting various types of solid tumors. On the other hand, the market also features a significant number of smaller biotech companies & startups that focus on developing specialized therapies of solid tumors or novel approaches to treatment.

USA Solid Tumor Therapeutics Market Analysis:

In May, 2022, the United States Department of Health & Human Services (HHS) awarded funding worth $5 million to community centers to increase equitable access to life-saving cancer screenings.

Around 1.9 million new cases were estimated to be diagnosed in United States in 2023, out of which 153,000 cases are colorectal cancer cases, 238,300 cases of lungs & bronchus cancers will be diagnosed. Therefore, the region's high burden of cases is projected to boost the R&D for solid tumor therapeutics.

As the number of elderly people grew within the United States, there was an increasing demand for cancer diagnosis. In 2022, breast, lungs, prostate & colorectal cancer accounted for the largest cases in the United States.

The US Food & Drug Administration (FDA), a government regulatory agency under the Health & Human Services, controls the drug approval process & is tasked with reviewing new drugs & devices before companies start selling them. The process involves discovery/concept, preclinical research, clinical research, FDA review & FDA post-market safety monitoring.

Key Trends by Market Segment:

By Type: Breast cancer has been the dominant segment in 2022, owing to the increasing number of breast cancer cases & other internal & external factors like genetics, lifestyle, environmental factors & awareness which are leading to early detection. Breast cancer market is forecasted to grow further, due to high burden of cancer & rising launches of market players.

By Application: Cancer research center has been the dominant market in 2022. These centers' prominent focus is on cancer care, as they offer diagnostic capabilities, cutting edge treatments, clinical trials & comprehensive support care services.

By Geography: In 2022, the Northern area of the USA which includes states like New York, Massachusetts & Pennsylvania dominate the solid tumor therapeutics market in the United States because of major medical & research institutions, making it a hub for biotechnology & pharmaceutical companies.

Southern regions which include Texas, Florida & North Carolina, also has several prominent medical centers & cancer treatment facilities.

Eastern regions include New York, New Jersey & Massachusetts consists of some of the prestigious universities & research institutions. They have a stronger emphasis on research, clinical trials & developing novel therapies for treatment.

Western regions including California, Washington & Colorado is known for its biotech & pharmaceutical industry presence. Silicon Valley & San Francisco Bay Area have numerous companies & research institutions focusing on healthcare & oncology.

Competitive Landscape:

The USA Solid Tumor Therapeutics market consists of a wide range of companies- from pharmaceutical giants such as Pfizer & Novartis, which have a vast portfolio of oncology drugs that target various kinds of tumors including breast lungs & colorectal cancers. Numerous biotech firms are engaged in developing cutting edge therapies for solid tumors. Companies like Amgen, Gilead Sciences & Celgene have been at the forefront of research & innovation in this field. Targeted therapies which focus on specific genetic mutations or protein expressions have gained prominence. Companies like AstraZeneca, Pfizer & Bayer have started developing targeted therapies that cater to the unique characteristics of different solid tumors. The solid tumor market continues to attract small & emerging biotech companies that are working on novel approaches. These companies often focus on niche indications or unique mechanisms of action, attempting to bring innovation in market.

Recent Developments:

Eli Lilly & Company received the United States Food & Drug Administration (FDA) approval for Retevmo (selpractinib capsules) for adult patients with locally advanced or metastatic solid tumors.

Researchers at City of Hope, one of the largest cancer research & treatment organizations in the United States, developed targeted chemotherapy which developed cell nuclear antigen (CNA) that appears to annihilate all solid tumors in preclinical research.

Researchers at the University of Buffalo (New York, USA), receive a $3 million grant to study human cells therapy for tumors. Whilst CAR-T therapies have received FDA approval for treating hematopoietic cancer, their use in tumors has remained unsuccessful. They will study this, using animal tumor models & tumor stroma-on-the-chip technology.

Future Outlook:

USA Solid Tumor Therapeutics Market is expected to show increasing and is expected to grow at a CAGR of ~10% from 2022 to 2028 with technological advancements, regulatory policies & healthcare policies leading to advancing growth of the market.

The field of oncology is moving towards more personalized treatment approaches, where therapies are tailored to an individual patient's genetic & molecular profile.

Immunotherapies like immune checkpoint inhibitors and CAR-T cell therapies, has shown positive results in treating certain types of solid tumors. Ongoing research & development in this area can lead to expansion of immunotherapy applications to a wide range of settings.

The discovery & development of new drug classes, such as small molecule inhibitors & antibody drug conjugates, could provide additional treatment options for solid tumor patients.

Advances in diagnostic technologies, such as liquid biopsies and advanced imaging techniques, could lead to earlier & more accurate detection, enabling timely interventions.